

# Dopamine activation of endogenous cannabinoid signal

Nature Neuroscience

2, 358-363

DOI: [10.1038/7268](https://doi.org/10.1038/7268)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12198-12203.	3.3	450
2	Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience, 1999, 11, 4213-4225.	1.2	792
3	Anandamide: a candidate neurotransmitter heads for the big leagues. Nature Neuroscience, 1999, 2, 303-304.	7.1	27
4	Effects of $\delta^9$ -THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. Brain Research, 1999, 841, 114-122.	1.1	25
6	A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Progress in Brain Research, 2000, 129, 471-482.	0.9	28
7	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817.	1.7	113
8	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817-824.	1.7	315
9	Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study. Synapse, 2000, 37, 71-80.	0.6	194
10	Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry. Analytical Biochemistry, 2000, 280, 87-93.	1.1	152
11	2-Arachidonoylglycerol and the cannabinoid receptors. Chemistry and Physics of Lipids, 2000, 108, 89-106.	1.5	205
12	N-Acylethanolamines and precursor phospholipids $\hat{a}$ relation to cell injury. Chemistry and Physics of Lipids, 2000, 108, 135-150.	1.5	214
13	The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chemistry and Physics of Lipids, 2000, 108, 151-158.	1.5	50
14	The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews, 2000, 24, 417-463.	2.9	4,590
15	Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 2000, 404, 84-87.	13.7	522
16	Endogenous cannabinoid signaling and psychomotor disorders. Prostaglandins and Other Lipid Mediators, 2000, 61, 63-70.	1.0	10
17	Permissive Role of Dopamine D2 Receptors in the Hypothermia Induced by $\delta^9$ -Tetrahydrocannabinol in Rats. Pharmacology Biochemistry and Behavior, 2000, 66, 183-187.	1.3	47
18	Fine Motor Control in Rats is Disrupted by Delta-9-Tetrahydrocannabinol. Pharmacology Biochemistry and Behavior, 2000, 66, 803-809.	1.3	15
19	The ratio of striatal D1 to muscarinic receptors changes in aging rats housed in an enriched environment. Brain Research, 2000, 872, 262-265.	1.1	6

#	ARTICLE	IF	CITATIONS
20	Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. <i>European Journal of Pharmacology</i> , 2000, 408, 161-168.	1.7	118
21	Endocannabinoids and Peripheral Pain. <i>Pharmacy and Pharmacology Communications</i> , 2000, 6, 259-262.	0.3	0
22	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. <i>FASEB Journal</i> , 2000, 14, 1432-1438.	0.2	292
23	Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice. <i>Journal of Neuroscience</i> , 2000, 20, 9284-9289.	1.7	105
24	Cannabinoids Modulate Synaptic Strength and Plasticity at Glutamatergic Synapses of Rat Prefrontal Cortex Pyramidal Neurons. <i>Journal of Neurophysiology</i> , 2000, 83, 3287-3293.	0.9	259
25	Reversal of Dopamine D <sub>2</sub> Receptor Responses by an Anandamide Transport Inhibitor. <i>Journal of Neuroscience</i> , 2000, 20, 3401-3407.	1.7	220
26	When and Where Are N-Acylethanolamine Phospholipids and Anandamide Formed?. , 2000, 88, 223-227.		3
27	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. <i>FASEB Journal</i> , 2000, 14, 1432-1438.	0.2	227
28	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. <i>Biochemical and Biophysical Research Communications</i> , 2000, 270, 260-266.	1.0	172
29	The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA <sub>A</sub> receptor alterations in the human basal ganglia in Huntington's disease. <i>Neuroscience</i> , 2000, 97, 505-519.	1.1	492
30	Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. <i>Neuroscience</i> , 2000, 98, 705-713.	1.1	162
31	The endocannabinoid system as a target for therapeutic drugs. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 218-224.	4.0	401
32	Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. <i>Peptides</i> , 2000, 21, 1735-1742.	1.2	302
33	Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1535, 78-86.	1.8	123
34	Cannabis use is associated with schizotypy and attentional disinhibition. <i>Schizophrenia Research</i> , 2001, 48, 83-92.	1.1	146
35	Endocannabinoids control spasticity in a multiple sclerosis model. <i>FASEB Journal</i> , 2001, 15, 300-302.	0.2	371
36	Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease. <i>Experimental Neurology</i> , 2001, 169, 400-406.	2.0	73
37	The role of Cannabinoids in neurodegenerative diseases. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 743-765.	2.5	65

#	ARTICLE	IF	CITATIONS
38	Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. <i>Neuroscience Letters</i> , 2001, 297, 175-178.	1.0	57
39	Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals. <i>Neuron</i> , 2001, 29, 729-738.	3.8	754
40	Chronic treatment with $\delta^9$ -tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. <i>Neuropharmacology</i> , 2001, 41, 118-129.	2.0	111
41	The neurobiology and evolution of cannabinoid signalling. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 381-408.	1.8	338
42	CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum. <i>Journal of Neurophysiology</i> , 2001, 85, 468-471.	0.9	412
43	Metabotropic Glutamate Receptors Drive the Endocannabinoid System in Hippocampus. <i>Journal of Neuroscience</i> , 2001, 21, RC188-RC188.	1.7	347
44	Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration. <i>Journal of Neuroscience</i> , 2001, 21, 5344-5350.	1.7	347
45	Exogenous Anandamide Protects Rat Brain against Acute Neuronal Injury <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2001, 21, 8765-8771.	1.7	180
46	SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. <i>Psychopharmacology</i> , 2001, 157, 254-259.	1.5	69
47	Behavioural sensitization after repeated exposure to $\delta^9$ -tetrahydrocannabinol and cross-sensitization with morphine. <i>Psychopharmacology</i> , 2001, 158, 259-266.	1.5	151
48	Impaired sodium excretion, decreased glomerular filtration rate and elevated blood pressure in endothelin receptor type B deficient rats. <i>Journal of Molecular Medicine</i> , 2001, 78, 633-641.	1.7	22
49	Control of the cell survival/death decision by cannabinoids. <i>Journal of Molecular Medicine</i> , 2001, 78, 613-625.	1.7	207
50	Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson's disease and schizophrenia. <i>Neurotoxicity Research</i> , 2001, 3, 23-35.	1.3	54
51	Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. <i>Journal of Neurochemistry</i> , 2001, 76, 594-601.	2.1	92
52	Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. <i>FEBS Journal</i> , 2001, 268, 819-825.	0.2	65
53	Stereochemical Selectivity of Methanandamides for the CB1 and CB2 Cannabinoid Receptors and Their Metabolic Stability. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 1673-1684.	1.4	48
54	Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. <i>European Journal of Neuroscience</i> , 2001, 14, 96-102.	1.2	78
55	Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. <i>European Journal of Neuroscience</i> , 2001, 14, 1827-1832.	1.2	166

#	ARTICLE	IF	CITATIONS
56	Schizophrenia and the cannabinoid receptor type 1 (CB1): Association study using a single-base polymorphism in coding exon 1. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 749-752.	2.4	101
57	The endocannabinoid anandamide is a direct and selective blocker of the background K <sup>+</sup> channel TASK-1. <i>EMBO Journal</i> , 2001, 20, 47-54.	3.5	270
58	Cannabinoid activity curtails cocaine craving. <i>Nature Medicine</i> , 2001, 7, 1099-1100.	15.2	12
59	A cannabinoid mechanism in relapse to cocaine seeking. <i>Nature Medicine</i> , 2001, 7, 1151-1154.	15.2	398
60	Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. <i>Molecular Psychiatry</i> , 2001, 6, 501-502.	4.1	46
61	An anorexic lipid mediator regulated by feeding. <i>Nature</i> , 2001, 414, 209-212.	13.7	646
62	The endocannabinoid nervous system. , 2001, 90, 45-60.		218
63	Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. <i>European Journal of Pharmacology</i> , 2001, 419, 191-198.	1.7	219
64	Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. <i>European Journal of Pharmacology</i> , 2001, 420, 123-131.	1.7	113
65	Receptor-dependent formation of endogenous cannabinoids in cortical neurons. <i>European Journal of Pharmacology</i> , 2001, 425, 189-196.	1.7	204
66	ARPP-16/ARPP-19: a highly conserved family of cAMP-regulated phosphoproteins. <i>Journal of Neurochemistry</i> , 2001, 77, 229-238.	2.1	57
67	Dual Role of Fyn in the Regulation of FAK+6,7 by Cannabinoids in Hippocampus. <i>Journal of Biological Chemistry</i> , 2001, 276, 38289-38296.	1.6	53
68	Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716. <i>Archives of General Psychiatry</i> , 2001, 58, 322.	13.8	437
69	Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2001, 5, 349-362.	1.5	4
70	Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. <i>Vitamins and Hormones</i> , 2001, 62, 95-131.	0.7	68
71	The Decade 1989â€“1998 in Spanish Psychology: An Analysis of Research in Psychobiology. <i>Spanish Journal of Psychology</i> , 2001, 4, 219-236.	1.1	2
72	Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8384-8388.	3.3	524
73	Brain monoglyceride lipase participating in endocannabinoid inactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10819-10824.	3.3	1,206

#	ARTICLE	IF	CITATIONS
74	Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. <i>Journal of Psychopharmacology</i> , 2002, 16, 139-143.	2.0	73
75	The Endocannabinoid Anandamide Inhibits Neuronal Progenitor Cell Differentiation through Attenuation of the Rap1/B-Raf/ERK Pathway. <i>Journal of Biological Chemistry</i> , 2002, 277, 46645-46650.	1.6	212
76	Combined Treatment of Tourette Syndrome with $\delta^9$ -THC and Dopamine Receptor Antagonists. <i>Journal of Cannabis Therapeutics</i> , 2002, 2, 145-154.	1.2	12
77	Release of Fatty Acid Amides in a Patient With Hemispheric Stroke. <i>Stroke</i> , 2002, 33, 2112-2114.	1.0	113
78	Astrocytes in Culture Produce Anandamide and Other Acylethanolamides. <i>Journal of Biological Chemistry</i> , 2002, 277, 20869-20876.	1.6	162
79	The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. <i>NeuroReport</i> , 2002, 13, 1833-1841.	0.6	37
81	Marijuana and movement disorders. , 2002, , .		0
82	Behavioral Neurobiology of Alcohol Addiction: Recent Advances and Challenges. <i>Journal of Neuroscience</i> , 2002, 22, 3332-3337.	1.7	295
83	International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. <i>Pharmacological Reviews</i> , 2002, 54, 161-202.	7.1	2,347
84	Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 287-299.	1.0	80
85	Endocannabinoids and their actions. <i>Vitamins and Hormones</i> , 2002, 65, 225-255.	0.7	64
86	Cannabinoid receptors and their ligands. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 101-121.	1.0	477
87	Endocannabinoids and basal ganglia functionality. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 257-267.	1.0	52
88	Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 173-192.	1.0	301
89	Endocannabinoids in the central nervous system-an overview. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 221-233.	1.0	161
90	A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and a posterior hyperfunctioning mesocorticolimbic system. <i>Behavioural Brain Research</i> , 2002, 130, 171-179.	1.2	51
91	Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. <i>Progress in Neurobiology</i> , 2002, 68, 247-286.	2.8	531
92	Donn�es neurobiologiques r�centes sur le cannabis. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2002, 186, 319-329.	0.0	2

#	ARTICLE	IF	CITATIONS
93	Neurobiology of Relapse to Heroin and Cocaine Seeking: A Review. <i>Pharmacological Reviews</i> , 2002, 54, 1-42.	7.1	774
94	Cannabinoid Addiction: Behavioral Models and Neural Correlates. <i>Journal of Neuroscience</i> , 2002, 22, 3326-3331.	1.7	192
95	Activation of Muscarinic Acetylcholine Receptors Enhances the Release of Endogenous Cannabinoids in the Hippocampus. <i>Journal of Neuroscience</i> , 2002, 22, 10182-10191.	1.7	279
96	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. <i>Journal of Neuroscience</i> , 2002, 22, 6900-6907.	1.7	303
97	Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. <i>European Journal of Pharmacology</i> , 2002, 454, 145-151.	1.7	22
98	Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. <i>European Journal of Pharmacology</i> , 2002, 454, 103-104.	1.7	37
99	The cannabinoid receptors. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 619-631.	1.0	406
100	From cannabis to cannabinergics. , 2002, 95, 103-117.		88
101	The endogenous cannabinoid system and the basal ganglia. , 2002, 95, 137-152.		126
102	Cannabinoids and cell fate. , 2002, 95, 175-184.		148
103	Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. <i>Developmental Brain Research</i> , 2002, 136, 85-92.	2.1	74
104	Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of $\delta^9$ -Tetrahydrocannabinol-Tolerant Rats. <i>Journal of Neurochemistry</i> , 2002, 74, 1627-1635.	2.1	144
105	Determination of the Phospholipid Precursor of Anandamide and Other N-Acylethanolamine Phospholipids Before and After Sodium Azide-Induced Toxicity in Cultured Neocortical Neurons. <i>Journal of Neurochemistry</i> , 2002, 75, 861-871.	2.1	55
106	Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. <i>Nature Neuroscience</i> , 2002, 5, 446-451.	7.1	670
107	Is cannabinoid transmission involved in rewarding properties of drugs of abuse?. <i>British Journal of Pharmacology</i> , 2002, 136, 1083-1084.	2.7	4
108	Ethanol, Endocannabinoids, and the Cannabinoidergic Signaling System. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 565-574.	1.4	80
109	A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. <i>Chemistry and Physics of Lipids</i> , 2002, 121, 149-158.	1.5	285
110	Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges. <i>Chemistry and Physics of Lipids</i> , 2002, 121, 111-134.	1.5	65

#	ARTICLE	IF	CITATIONS
111	Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 1020-1024.	1.3	531
112	Cannabis and the brain. <i>Brain</i> , 2003, 126, 1252-1270.	3.7	666
113	Exogenous and Endogenous Cannabinoids Control Synaptic Transmission in Mice Nucleus Accumbens. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 212-225.	1.8	70
114	Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 368, 432-436.	1.4	18
115	The reinstatement model of drug relapse: history, methodology and major findings. <i>Psychopharmacology</i> , 2003, 168, 3-20.	1.5	1,484
116	Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. <i>Psychopharmacology</i> , 2003, 168, 164-169.	1.5	174
117	The therapeutic potential of cannabis. <i>Lancet Neurology</i> , The, 2003, 2, 291-298.	4.9	299
118	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. <i>European Journal of Pharmacology</i> , 2003, 480, 133-150.	1.7	249
119	Perinatal exposure to $\delta^9$ -tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 565-575.	1.3	31
120	Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 138-149.	2.2	75
121	The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. <i>Neuroscience and Biobehavioral Reviews</i> , 2003, 27, 639-651.	2.9	179
122	Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. <i>Journal of Neurochemistry</i> , 2003, 84, 698-704.	2.1	304
123	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. <i>Journal of Neurochemistry</i> , 2003, 85, 1018-1025.	2.1	145
124	Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. <i>European Journal of Neuroscience</i> , 2003, 18, 1607-1614.	1.2	144
125	The molecular logic of endocannabinoid signalling. <i>Nature Reviews Neuroscience</i> , 2003, 4, 873-884.	4.9	1,745
126	Emerging roles for endocannabinoids in long-term synaptic plasticity. <i>British Journal of Pharmacology</i> , 2003, 140, 781-789.	2.7	121
127	Modulation of anxiety through blockade of anandamide hydrolysis. <i>Nature Medicine</i> , 2003, 9, 76-81.	15.2	1,306
128	Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases. <i>Neurotoxicity Research</i> , 2003, 5, 183-199.	1.3	19



#	ARTICLE	IF	CITATIONS
129	Potential of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats. <i>Neuroscience Letters</i> , 2003, 349, 49-52.	1.0	11
130	Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. <i>Neuroscience</i> , 2003, 119, 309-318.	1.1	167
131	It could be habit forming: drugs of abuse and striatal synaptic plasticity. <i>Trends in Neurosciences</i> , 2003, 26, 184-192.	4.2	443
132	Heterosynaptic LTD of Hippocampal GABAergic Synapses. <i>Neuron</i> , 2003, 38, 461-472.	3.8	581
133	Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2003, 1633, 61-67.	1.2	36
134	CB cannabinoid receptor signalling in Parkinson's disease. <i>Current Opinion in Pharmacology</i> , 2003, 3, 54-61.	1.7	151
135	Therapeutic Potential of Cannabinoids in CNS Disease. <i>CNS Drugs</i> , 2003, 17, 179-202.	2.7	211
136	Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 880-888.	1.3	144
137	Dopamine, Acetylcholine and Nitric Oxide Systems Interact to Induce Corticostriatal Synaptic Plasticity. <i>Reviews in the Neurosciences</i> , 2003, 14, 207-16.	1.4	110
138	Cannabinoids reduce symptoms of Tourette's syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1717-1725.	0.9	59
139	The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 93-102.	1.3	157
140	Role of Endogenous Cannabinoids in Synaptic Signaling. <i>Physiological Reviews</i> , 2003, 83, 1017-1066.	13.1	1,399
141	Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 459-465.	1.1	216
142	Neurodevelopment During Adolescence. , 2003, , 62-83.		27
143	Mediation of Amphetamine-Induced Long-Term Depression of Synaptic Transmission by CB <sub>1</sub> Cannabinoid Receptors in the Rat Amygdala. <i>Journal of Neuroscience</i> , 2003, 23, 10311-10320.	1.7	76
144	Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration. <i>Journal of Neuroscience</i> , 2003, 23, 1398-1405.	1.7	605
145	Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility. <i>Journal of Neuroscience</i> , 2003, 23, 7767-7775.	1.7	232
146	Cannabinoid Function in Spatial Learning: An Update. <i>Current Neuropharmacology</i> , 2004, 2, 125-143.	1.4	11

#	ARTICLE	IF	CITATIONS
147	Cannabinoid "model" psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. , 2004, , 142-165.		19
148	The endogenous cannabinoid system in schizophrenia. , 2004, , 127-141.		2
149	How cannabis works in the brain. , 2004, , 19-40.		5
150	Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms. Neuropsychopharmacology, 2004, 29, 2108-2114.	2.8	423
151	Experimental Parkinsonism Alters Anandamide Precursor Synthesis, and Functional Deficits are Improved by AM404: A Modulator of Endocannabinoid Function. Neuropsychopharmacology, 2004, 29, 1134-1142.	2.8	67
152	Disruption of Endocannabinoid Release and Striatal Long-Term Depression by Postsynaptic Blockade of Endocannabinoid Membrane Transport. Journal of Neuroscience, 2004, 24, 1673-1679.	1.7	216
153	D2 Dopamine Receptors Modulate G $\pm$ -Subunit Coupling of the CB1 Cannabinoid Receptor. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 880-886.	1.3	124
154	Food intake is inhibited by oral oleoylethanolamide. Journal of Lipid Research, 2004, 45, 1027-1029.	2.0	91
155	Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression. Journal of Neuroscience, 2004, 24, 10013-10021.	1.7	55
156	A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission. Neuropsychopharmacology, 2004, 29, 1488-1497.	2.8	139
157	Endocannabinoid System Modulates Relapse to Methamphetamine Seeking: Possible Mediation by the Arachidonic Acid Cascade. Neuropsychopharmacology, 2004, 29, 1470-1478.	2.8	115
158	Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience, 2004, 20, 1849-1857.	1.2	86
159	Endocannabinoids and Their Implications for Epilepsy. Epilepsy Currents, 2004, 4, 169-173.	0.4	51
160	Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). British Journal of Pharmacology, 2004, 142, 9-19.	2.7	230
161	Anandamide transport. , 2004, 104, 117-135.		93
162	Role of Endocannabinoids and Cannabinoid CB1 Receptors in Alcohol-Related Behaviors. Annals of the New York Academy of Sciences, 2004, 1025, 515-527.	1.8	62
163	Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cellular and Molecular Life Sciences, 2004, 61, 945-950.	2.4	127
164	Immunolocalization of CB1receptor in rat striatal neurons: A confocal microscopy study. Synapse, 2004, 53, 159-167.	0.6	75

#	ARTICLE	IF	CITATIONS
165	Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. <i>Journal of Neurochemistry</i> , 2004, 88, 1159-1167.	2.1	147
166	Cannabinoid signaling in glial cells. <i>Glia</i> , 2004, 48, 267-277.	2.5	207
167	Cannabis-Associated Psychosis. <i>CNS Drugs</i> , 2004, 18, 895-910.	2.7	53
168	Endocannabinoids and exercise. <i>British Journal of Sports Medicine</i> , 2004, 38, 536-541.	3.1	301
171	The endogenous cannabinoid system and the treatment of marijuana dependence. <i>Neuropharmacology</i> , 2004, 47, 359-367.	2.0	35
172	Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. <i>Neurobiology of Disease</i> , 2004, 16, 377-385.	2.1	43
173	Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. <i>Behavioural Pharmacology</i> , 2004, 15, 341-352.	0.8	227
174	New Perspectives in the Studies on Endocannabinoid and Cannabis: A Role for the Endocannabinoid-Arachidonic Acid Pathway in Drug Reward and Long-Lasting Relapse to Drug Taking. <i>Journal of Pharmacological Sciences</i> , 2004, 96, 382-388.	1.1	28
175	Schizophrenie et cannabinoïdes. <i>Drogues, Santé Et Société</i> , 2004, 2, .	0.1	3
176	Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. <i>Behavioural Pharmacology</i> , 2005, 16, 441-446.	0.8	15
177	Cannabinoids and Dopamine Receptors' Action on Calcium Current in Rat Neurons. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 529-537.	0.3	2
178	Endocannabinoids and Dopamine-Related Functions in the CNS. , 2005, , .		0
179	Behavioral Effects of Endocannabinoids. , 2005, , .		0
180	The Role of Endocannabinoids in the Development, Progression, and Treatment of Neurodegenerative Diseases. , 2005, , .		0
181	Occurrence, Biosynthesis, and Metabolism of Endocannabinoids. , 2005, , .		1
182	Man-Made Marijuana. , 2005, , .		1
183	Endocannabinoids and liver disease - review. <i>Liver International</i> , 2005, 25, 921-926.	1.9	34
184	Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. <i>European Journal of Neuroscience</i> , 2005, 21, 1057-1069.	1.2	260

#	ARTICLE	IF	CITATIONS
185	Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. <i>Journal of Physiology</i> , 2005, 562, 245-256.	1.3	90
186	Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D/D receptor agonists in the least shrew (). <i>Pharmacology Biochemistry and Behavior</i> , 2005, 80, 35-44.	1.3	42
187	Endocannabinoid signaling system and brain reward: Emphasis on dopamine. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 263-284.	1.3	350
188	Acute $\delta^9$ -tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 71-77.	1.3	14
189	The role of endocannabinoid transmission in cocaine addiction. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 396-406.	1.3	73
190	The challenge of brain lipidomics. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 77, 23-34.	1.0	42
191	Targeted lipidomics: fatty acid amides and pain modulation. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 77, 35-45.	1.0	40
192	Subchronic haloperidol increases CB1 receptor binding and G protein coupling in discrete regions of the basal ganglia. <i>Journal of Neuroscience Research</i> , 2005, 82, 264-272.	1.3	20
193	The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. <i>Psychopharmacology</i> , 2005, 177, 264-271.	1.5	41
194	The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. <i>Psychopharmacology</i> , 2005, 182, 262-276.	1.5	75
195	Levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2005, 112, 359-391.	1.4	91
196	Endogenous cannabinoids ? a local message in and between the nervous and immune system. <i>Signal Transduction</i> , 2005, 5, 19-27.	0.7	2
197	Talking Back: Endocannabinoid Retrograde Signaling Adjusts Synaptic Efficacy. , 2005, , 237-253.		1
198	Role of Endogenous Cannabinoids in Cognition and Emotionality. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 659-670.	1.1	75
199	ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL. <i>Alcohol and Alcoholism</i> , 2005, 40, 15-24.	0.9	55
200	CB1 Receptor Knockout Mice Display Reduced Ethanol-Induced Conditioned Place Preference and Increased Striatal Dopamine D2 Receptors. <i>Neuropsychopharmacology</i> , 2005, 30, 339-349.	2.8	172
201	Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. <i>Neuropsychopharmacology</i> , 2005, 30, 1670-1680.	2.8	197
202	Dopamine Modulation of State-Dependent Endocannabinoid Release and Long-Term Depression in the Striatum. <i>Journal of Neuroscience</i> , 2005, 25, 10537-10545.	1.7	315

#	ARTICLE	IF	CITATIONS
203	The Endogenous Cannabinoid Anandamide and Its Synthetic Analog R(+)-Methanandamide Are Intravenously Self-Administered by Squirrel Monkeys. <i>Journal of Neuroscience</i> , 2005, 25, 5645-5650.	1.7	91
204	A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. <i>FASEB Journal</i> , 2005, 19, 1140-1142.	0.2	189
205	Endocannabinoid Signaling Dynamics Probed with Optical Tools. <i>Journal of Neuroscience</i> , 2005, 25, 9449-9459.	1.7	60
206	Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk?. <i>Molecular Pharmacology</i> , 2005, 67, 1697-1704.	1.0	318
207	Endocannabinoid Identification in the Brain: Studies of Breakdown Lead to Breakthrough, and There May Be NO Hope. <i>Science Signaling</i> , 2005, 2005, pe51-pe51.	1.6	21
208	The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. <i>Peptides</i> , 2005, 26, 1346-1355.	1.2	40
209	THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. <i>Alcohol and Alcoholism</i> , 2005, 40, 2-14.	0.9	305
210	Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons. <i>Journal of Neuroscience</i> , 2005, 25, 8432-8438.	1.7	117
211	Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. <i>Neurobiology of Disease</i> , 2005, 18, 591-601.	2.1	92
212	Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. <i>Life Sciences</i> , 2005, 77, 1569-1583.	2.0	33
213	Cannabinoid CB1 receptors control conditioned drug seeking. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 420-426.	4.0	189
214	Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. <i>Neuropharmacology</i> , 2005, 49, 502-513.	2.0	42
215	Effects on Cell Viability. , 2005, , 627-642.		35
216	Cannabinoid Control of Motor Function at the Basal Ganglia. , 2005, , 479-507.		58
218	Section II. The Dopamine System. <i>International Review of Neurobiology</i> , 2005, 64, 123-172.	0.9	14
221	ENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS. <i>Annual Review of Neuroscience</i> , 2006, 29, 37-76.	5.0	691
222	Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications. <i>Biological Psychiatry</i> , 2006, 59, 508-515.	0.7	130
223	Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4650-4656.	2.9	58

#	ARTICLE	IF	CITATIONS
224	An Experimental Study of Catechol-O-Methyltransferase Val158Met Moderation of $\delta^9$ -Tetrahydrocannabinol-Induced Effects on Psychosis and Cognition. <i>Neuropsychopharmacology</i> , 2006, 31, 2748-2757.	2.8	288
225	The Endocannabinoid System as an Emerging Target of Pharmacotherapy. <i>Pharmacological Reviews</i> , 2006, 58, 389-462.	7.1	2,274
226	Comparing nucleus accumbens and dorsal striatal dopamine responses to self-administered cocaine in naïve rats. <i>Neuroscience Letters</i> , 2006, 408, 146-150.	1.0	8
227	Neuropsychology and neuropharmacology of P3a and P3b. <i>International Journal of Psychophysiology</i> , 2006, 60, 172-185.	0.5	611
228	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. <i>Progress in Lipid Research</i> , 2006, 45, 405-446.	5.3	314
229	The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells. <i>Neuron</i> , 2006, 49, 67-79.	3.8	390
230	Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. <i>Neuropharmacology</i> , 2006, 50, 372-379.	2.0	69
231	Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. <i>Neuropharmacology</i> , 2006, 50, 834-844.	2.0	112
232	Multiple Mechanisms of Endocannabinoid Response Initiation in Hippocampus. <i>Journal of Neurophysiology</i> , 2006, 95, 67-75.	0.9	109
233	Cell-cell communication by Endocannabinoids during Immune Surveillance of the Central Nervous System. , 2006, 43, 281-305.		7
234	Ryanodine Receptor Regulates Endogenous Cannabinoid Mobilization in the Hippocampus. <i>Journal of Neurophysiology</i> , 2006, 95, 3001-3011.	0.9	54
235	Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats. <i>Journal of Neurochemistry</i> , 2006, 97, 1145-1154.	2.1	24
236	Serotonin 5-HT <sub>2A</sub> receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. <i>Journal of Neurochemistry</i> , 2006, 99, 1164-1175.	2.1	54
237	Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597). <i>CNS Neuroscience &amp; Therapeutics</i> , 2006, 12, 21-38.	4.0	331
238	The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 124-134.	1.2	48
239	Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. <i>Psychopharmacology</i> , 2006, 188, 293-305.	1.5	46
240	Microdialysis as a tool in local pharmacodynamics. <i>AAPS Journal</i> , 2006, 8, E222-E235.	2.2	32
241	Cannabinoid receptors and endocannabinoids: Evidence for new players. <i>AAPS Journal</i> , 2006, 8, E298-E306.	2.2	208

#	ARTICLE	IF	CITATIONS
242	Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. <i>Brain Research</i> , 2006, 1073-1074, 209-219.	1.1	99
243	CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression. <i>Brain Research</i> , 2006, 1093, 20-24.	1.1	15
244	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Ila clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594.	2.2	99
245	Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 203-210.	1.5	36
246	Involvement of the Endocannabinoid System in the Ability of Long-Term Tricyclic Antidepressant Treatment to Suppress Stress-Induced Activation of the Hypothalamicâ€Pituitaryâ€Adrenal Axis. <i>Neuropsychopharmacology</i> , 2006, 31, 2591-2599.	2.8	110
247	Cannabinoid Receptors as Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2006, 12, 1751-1769.	0.9	55
248	Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404. <i>Neuropsychopharmacology</i> , 2006, 31, 2652-2659.	2.8	208
249	A biosynthetic pathway for anandamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13345-13350.	3.3	396
250	Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. <i>International Journal of Obesity</i> , 2006, 30, S19-S23.	1.6	86
251	Endocannabinoid system and its role in energy regulation. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 557-569.	1.2	4
252	Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8251-8256.	3.3	160
253	Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20564-20569.	3.3	98
254	Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects. <i>Molecular Pharmacology</i> , 2007, 71, 1445-1456.	1.0	71
255	Tonic Enhancement of Endocannabinoid-Mediated Retrograde Suppression of Inhibition by Cholinergic Interneuron Activity in the Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 496-506.	1.7	125
256	Anandamide Regulates Postnatal Development of Long-Term Synaptic Plasticity in the Rat Dorsolateral Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 2403-2409.	1.7	78
257	Role of Cannabinoid Type 1 Receptors in Locomotor Activity and Striatal Signaling in Response to Psychostimulants. <i>Journal of Neuroscience</i> , 2007, 27, 6937-6947.	1.7	115
258	Critical Enzymes Involved in Endocannabinoid Metabolism. <i>Protein and Peptide Letters</i> , 2007, 14, 237-246.	0.4	143
259	The Endocannabinoid Signaling System: A Potential Target for Next- Generation Therapeutics for Alcoholism. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 769-779.	1.1	45

#	ARTICLE	IF	CITATIONS
262	Cannabis and the brain. , 2007, , 81-100.		0
263	Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 318-326.	1.3	97
264	In Vivo Microdialysis: A Method for Sampling Extracellular Fluid in Discrete Brain Regions. , 2007, , 219-256.		3
265	Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity. Current Neuropharmacology, 2007, 5, 81-97.	1.4	98
266	Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?. Current Neuropharmacology, 2007, 5, 268-277.	1.4	41
267	Regulation of brain anandamide by acute administration of ethanol. Biochemical Journal, 2007, 404, 97-104.	1.7	101
268	Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences, 2007, 30, 211-219.	4.2	707
269	D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends in Neurosciences, 2007, 30, 228-235.	4.2	973
270	The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Progress in Neurobiology, 2007, 81, 349-379.	2.8	109
271	Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands. Behavioural Brain Research, 2007, 178, 274-282.	1.2	8
272	Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors. Experimental Neurology, 2007, 208, 110-119.	2.0	173
273	In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Current Opinion in Pharmacology, 2007, 7, 62-68.	1.7	27
274	Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. Diabetes and Metabolism, 2007, 33, 97-107.	1.4	21
275	Functional neurochemistry of the basal ganglia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 19-66.	1.0	12
276	Endocannabinoid regulation of relapse mechanisms. Pharmacological Research, 2007, 56, 418-427.	3.1	47
277	Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacological Research, 2007, 56, 393-405.	3.1	86
278	Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophrenia Research, 2007, 94, 29-36.	1.1	219
279	Endocannabinoid signaling is critical for habit formation. Frontiers in Integrative Neuroscience, 2007, 1, 6.	1.0	142



#	ARTICLE	IF	CITATIONS
280	CNR1 Variation Modulates Risk for Drug and Alcohol Dependence. <i>Biological Psychiatry</i> , 2007, 62, 616-626.	0.7	105
281	Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. <i>Nature</i> , 2007, 445, 643-647.	13.7	653
282	Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. <i>European Journal of Neuroscience</i> , 2007, 25, 1631-1640.	1.2	37
283	Ethanol reverses the direction of long-term synaptic plasticity in the dorsomedial striatum. <i>European Journal of Neuroscience</i> , 2007, 25, 3226-3232.	1.2	95
284	CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis) in the rat striatum. <i>Journal of Neurochemistry</i> , 2007, 101, 389-396.	1.2	56
285	CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. <i>Journal of Neurochemistry</i> , 2007, 101, 389-396.	2.1	41
286	An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives. <i>Brain Research Reviews</i> , 2007, 53, 1-16.	9.1	90
287	Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. <i>European Journal of Pharmacology</i> , 2007, 559, 180-183.	1.7	28
288	Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2. <i>European Journal of Pharmacology</i> , 2007, 563, 141-148.	1.7	44
289	Immune control by endocannabinoids - New mechanisms of neuroprotection?. <i>Journal of Neuroimmunology</i> , 2007, 184, 127-135.	1.1	52
290	In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1719-1726.	3.3	20
292	Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. <i>Journal of Neural Transmission</i> , 2007, 114, 1055-1063.	1.4	159
293	Endocannabinoid Liberation from Neurons in Transsynaptic Signaling. <i>Journal of Molecular Neuroscience</i> , 2007, 33, 87-93.	1.1	23
294	Secondary metabolism in cannabis. <i>Phytochemistry Reviews</i> , 2008, 7, 615-639.	3.1	268
295	What is the mechanism whereby cannabis use increases risk of psychosis?. <i>Neurotoxicity Research</i> , 2008, 14, 105-112.	1.3	53
296	Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716A) in the rat. <i>Journal of Neurochemistry</i> , 2008, 105, 107-115.	1.4	20
297	Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. <i>Psychopharmacology</i> , 2008, 197, 549-556.	1.5	70
298	Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. <i>Psychopharmacology</i> , 2008, 198, 449-460.	1.5	103

#	ARTICLE	IF	CITATIONS
299	Gene expression of opioid and dopamine systems in mouse striatum: effects of CB1 receptors, age and sex. <i>Psychopharmacology</i> , 2008, 198, 497-508.	1.5	12
300	ARPP-16/ARPP-19: a highly conserved family of cAMP-regulated phosphoproteins. <i>Journal of Neurochemistry</i> , 2008, 77, 229-238.	2.1	3
301	Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. <i>Journal of Comparative Neurology</i> , 2008, 509, 400-421.	0.9	122
302	An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. <i>Analytical Biochemistry</i> , 2008, 373, 220-228.	1.1	46
303	Neurobiological Processes in Adolescent Addictive Disorders. <i>American Journal on Addictions</i> , 2008, 17, 6-23.	1.3	81
304	The endocannabinoid system in brain reward processes. <i>British Journal of Pharmacology</i> , 2008, 154, 369-383.	2.7	211
305	Pharmacological activation of CB1 and D2 receptors in rats: predominant role of CB1 in the increase of alcohol relapse. <i>European Journal of Neuroscience</i> , 2008, 27, 3292-3298.	1.2	27
306	Cannabis and psychiatric disorders: it is not only addiction. <i>Addiction Biology</i> , 2008, 13, 264-275.	1.4	179
307	Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. <i>Addiction Biology</i> , 2008, 13, 253-263.	1.4	279
308	Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. <i>Brain Research Reviews</i> , 2008, 58, 415-452.	9.1	192
309	The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 89, 384-391.	1.3	37
310	Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1037-1048.	1.4	102
311	CB1 Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement. <i>Biological Psychiatry</i> , 2008, 63, 1030-1038.	0.7	42
312	Pharmacology of Neurotransmitter Release. <i>Handbook of Experimental Pharmacology</i> , 2008, , .	0.9	15
313	Regulation of Synaptic Function by Endocannabinoids. , 2008, , 771-792.		1
314	Cannabinoids and the Brain. , 2008, , .		8
315	Striatal Plasticity and Basal Ganglia Circuit Function. <i>Neuron</i> , 2008, 60, 543-554.	3.8	855
316	Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling. <i>Neuropharmacology</i> , 2008, 54, 79-86.	2.0	25

#	ARTICLE	IF	CITATIONS
317	Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. <i>Neuropharmacology</i> , 2008, 54, 815-823.	2.0	154
318	Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. <i>Neuropharmacology</i> , 2008, 55, 1183-1190.	2.0	28
319	Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. <i>Neuropharmacology</i> , 2008, 55, 1095-1104.	2.0	24
320	The cannabinoid system in Parkinson's disease: Multiple targets to motor effects. <i>Experimental Neurology</i> , 2008, 211, 334-338.	2.0	28
321	The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. <i>Behavioural Brain Research</i> , 2008, 187, 289-296.	1.2	48
322	Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. <i>Progress in Brain Research</i> , 2008, 170, 397-432.	0.9	144
323	Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 905-23.	1.0	34
324	Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors. <i>Neuropsychopharmacology</i> , 2008, 33, 1667-1679.	2.8	135
325	The Endocannabinoid System in Parkinsons Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 2337-2346.	0.9	52
326	Endocannabinoid Signaling Mediates Cocaine-Induced Inhibitory Synaptic Plasticity in Midbrain Dopamine Neurons. <i>Journal of Neuroscience</i> , 2008, 28, 1385-1397.	1.7	129
327	Metaplastic control of the endocannabinoid system at inhibitory synapses in hippocampus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8142-8147.	3.3	54
328	Cannabinoid CB1 Receptor Antagonists Attenuate Cocaine's Rewarding Effects: Experiments with Self-Administration and Brain-Stimulation Reward in Rats. <i>Neuropsychopharmacology</i> , 2008, 33, 1735-1745.	2.8	100
329	Presynaptic Modulation by Endocannabinoids. <i>Handbook of Experimental Pharmacology</i> , 2008, , 435-477.	0.9	203
331	Dopamine Receptor Activation Facilitates Endocannabinoid-Mediated Long-Term Synaptic Depression of GABAergic Synaptic Transmission in Midbrain Dopamine Neurons via cAMP-Protein Kinase A Signaling. <i>Journal of Neuroscience</i> , 2008, 28, 14018-14030.	1.7	115
332	Implication of the Endocannabinoid System in the Locomotor Hyperactivity Associated with Congenital Hypothyroidism. <i>Endocrinology</i> , 2008, 149, 2657-2666.	1.4	12
333	Chapter 4.5 The endocannabinoid system and anxiety responses. <i>Handbook of Behavioral Neuroscience</i> , 2008, , 303-324.	0.7	7
334	Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. <i>Journal of Psychopharmacology</i> , 2008, 22, 262-269.	2.0	45
335	The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2008, 14, 2370-2382.	0.9	83

#	ARTICLE	IF	CITATIONS
336	Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction. <i>Current Drug Abuse Reviews</i> , 2008, 1, 303-327.	3.4	68
337	High on habits. <i>Frontiers in Neuroscience</i> , 2008, 2, 208-217.	1.4	46
338	Detection of Heteromers Formed by Cannabinoid CB <sub>1</sub> , Dopamine D <sub>2</sub> , and Adenosine A <sub>2A</sub> -G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer. <i>Scientific World Journal</i> , The, 2008, 8, 1088-1097.	0.8	105
339	Discovery of Drugs to Treat Cocaine Dependence: Behavioral and Neurochemical Effects of Atypical Dopamine Transport Inhibitors. <i>Advances in Pharmacology</i> , 2009, 57, 253-289.	1.2	61
340	Adenylyl Cyclase Type 5 Contributes to Corticostriatal Plasticity and Striatum-Dependent Learning. <i>Journal of Neuroscience</i> , 2009, 29, 12115-12124.	1.7	78
342	Endocannabinoid Signaling in Neural Plasticity. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 1, 141-172.	0.8	21
343	A Role for the Endocannabinoid System in the Increased Motivation for Cocaine in Extended-Access Conditions. <i>Journal of Neuroscience</i> , 2009, 29, 4846-4857.	1.7	97
344	Interaction between Two Independent CNR1 Variants Increases Risk for Cocaine Dependence in European Americans: A Replication Study in Family-Based Sample and Population-Based Sample. <i>Neuropsychopharmacology</i> , 2009, 34, 1504-1513.	2.8	56
345	Role of the Endocannabinoid System in Ethanol-Induced Inhibition of Salivary Secretion. <i>Alcohol and Alcoholism</i> , 2009, 44, 443-448.	0.9	22
346	Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2009, 36, 51-59.	2.1	108
347	Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. <i>Neurobiology of Disease</i> , 2009, 36, 70-80.	2.1	40
348	Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. <i>Current Opinion in Neurobiology</i> , 2009, 19, 621-628.	2.0	150
349	Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism. <i>Brain Research</i> , 2009, 1260, 7-14.	1.1	10
350	Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. <i>Journal of Neural Transmission</i> , 2009, 116, 923-939.	1.4	42
351	Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 395-412.	1.8	142
352	Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. <i>Psychopharmacology</i> , 2009, 204, 1-11.	1.5	68
353	The endocannabinoid system as a target for modelling psychosis. <i>Psychopharmacology</i> , 2009, 206, 551-561.	1.5	42
354	Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. <i>Synapse</i> , 2009, 63, 941-950.	0.6	18

#	ARTICLE	IF	CITATIONS
355	The endocannabinoid system as a target for the treatment of motor dysfunction. <i>British Journal of Pharmacology</i> , 2009, 156, 1029-1040.	2.7	168
356	Positive allosteric modulation of the human cannabinoid (CB <sub>1</sub> ) receptor by RTI-371, a selective inhibitor of the dopamine transporter. <i>British Journal of Pharmacology</i> , 2009, 156, 1178-1184.	2.7	72
357	Endocannabinoid Signaling and Long-Term Synaptic Plasticity. <i>Annual Review of Physiology</i> , 2009, 71, 283-306.	5.6	400
358	Endocannabinoids as Modulators of Synaptic Signaling. , 2009, , 281-308.		4
359	Physiology and Pharmacology of Striatal Neurons. <i>Annual Review of Neuroscience</i> , 2009, 32, 127-147.	5.0	413
360	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. <i>Behavioural Brain Research</i> , 2009, 199, 108-118.	1.2	115
361	Metaplasticity of Hypothalamic Synapses following In Vivo Challenge. <i>Neuron</i> , 2009, 62, 839-849.	3.8	33
362	Looking for the role of cannabinoid receptor heteromers in striatal function. <i>Neuropharmacology</i> , 2009, 56, 226-234.	2.0	82
363	Endocannabinoid signaling in microglial cells. <i>Neuropharmacology</i> , 2009, 56, 244-253.	2.0	236
364	TRPV1 channels facilitate glutamate transmission in the striatum. <i>Molecular and Cellular Neurosciences</i> , 2009, 40, 89-97.	1.0	124
365	Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. <i>Neurochemistry International</i> , 2009, 54, 56-64.	1.9	42
366	Evidence for a Re-Evaluation of the Neurochemical and Anatomical Bases of Chemotherapy-Induced Vomiting. <i>Chemical Reviews</i> , 2009, 109, 3158-3199.	23.0	100
367	Chapter 9 The Endocannabinoid Anandamide. <i>Vitamins and Hormones</i> , 2009, 81, 207-230.	0.7	19
368	From Real-World Events to Psychosis: The Emerging Neuropharmacology of Delusions. <i>Schizophrenia Bulletin</i> , 2009, 35, 668-674.	2.3	43
369	Comorbid Mood, Psychosis, and Marijuana Abuse Disorders: A Theoretical Review. <i>Journal of Addictive Diseases</i> , 2009, 28, 309-319.	0.8	29
370	Chapter 4 Anandamide Receptor Signal Transduction. <i>Vitamins and Hormones</i> , 2009, 81, 79-110.	0.7	14
371	Endocannabinoid-Mediated Control of Synaptic Transmission. <i>Physiological Reviews</i> , 2009, 89, 309-380.	13.1	1,262
372	Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 599.	1.0	81

#	ARTICLE	IF	CITATIONS
373	Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration. Mini-Reviews in Medicinal Chemistry, 2009, 9, 448-462.	1.1	71
374	Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D2-induced formation of anandamide. Psychopharmacology, 2010, 209, 191-202.	1.5	22
375	Properties of cannabinoid-dependent long-term depression in the leech. Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology, 2010, 196, 841-851.	0.7	9
376	Pharmacology of signaling induced by dopamine D1-like receptor activation. , 2010, 128, 37-60.		111
377	Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behavioral and Brain Functions, 2010, 6, 19.	1.4	30
378	In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Research, 2010, 1316, 153-162.	1.1	38
379	Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding. Synapse, 2010, 64, 617-623.	0.6	13
380	Cue- conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. British Journal of Pharmacology, 2010, 159, 534-542.	2.7	41
381	The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 2010, 160, 480-498.	2.7	161
382	Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. British Journal of Pharmacology, 2010, 160, 423-442.	2.7	130
383	Competitive regulation of synaptic Ca <sup>2+</sup> influx by D2 dopamine and A2A adenosine receptors. Nature Neuroscience, 2010, 13, 958-966.	7.1	226
384	Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. European Journal of Neuroscience, 2010, 31, 14-28.	1.2	87
385	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. PLoS ONE, 2010, 5, e11464.	1.1	119
386	The Cholinergic Interneurons of the Striatum. Handbook of Behavioral Neuroscience, 2010, , 133-149.	0.7	13
387	Endocannabinoid Signaling in the Striatum. Handbook of Behavioral Neuroscience, 2010, , 167-186.	0.7	6
388	D1 and D2 Dopamine Receptor Modulation of Glutamatergic Signaling in Striatal Medium Spiny Neurons. Handbook of Behavioral Neuroscience, 2010, , 113-132.	0.7	4
389	Brain-Derived Neurotrophic Factor Controls Cannabinoid CB1 Receptor Function in the Striatum. Journal of Neuroscience, 2010, 30, 8127-8137.	1.7	59
390	Endocannabinoid Signaling Mediates Psychomotor Activation by Adenosine A <sub>2A</sub> Antagonists. Journal of Neuroscience, 2010, 30, 2160-2164.	1.7	74

#	ARTICLE	IF	CITATIONS
391	Ligand-Induced Regulation and Localization of Cannabinoid CB1 and Dopamine D2L Receptor Heterodimers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 710-719.	1.3	59
392	Endocannabinoids and Schizophrenia. <i>Pharmaceuticals</i> , 2010, 3, 3101-3126.	1.7	27
393	The role of dopamine in modulating the structure and function of striatal circuits. <i>Progress in Brain Research</i> , 2010, 183, 148-167.	0.9	65
394	Dopaminergic Modulation of Endocannabinoid-Mediated Plasticity at GABAergic Synapses in the Prefrontal Cortex. <i>Journal of Neuroscience</i> , 2010, 30, 7236-7248.	1.7	129
395	Voluntary Exercise and Sucrose Consumption Enhance Cannabinoid CB1 Receptor Sensitivity in the Striatum. <i>Neuropsychopharmacology</i> , 2010, 35, 374-387.	2.8	74
396	Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. <i>Pharmaceuticals</i> , 2010, 3, 2799-2820.	1.7	12
397	A Putative "Pre-Nervous" Endocannabinoid System in Early Echinoderm Development. <i>Developmental Neuroscience</i> , 2010, 32, 1-18.	1.0	19
398	Risperidone Treatment Increases CB <sub>1</sub> Receptor Binding in Rat Brain. <i>Neuroendocrinology</i> , 2010, 91, 155-168.	1.2	24
399	Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 373.	1.0	86
400	Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 101-107.	1.1	79
401	Dopamine Release and Uptake Impairments and Behavioral Alterations Observed in Mice that Model Fragile X Mental Retardation Syndrome. <i>ACS Chemical Neuroscience</i> , 2010, 1, 679-690.	1.7	33
402	Endocannabinoid signaling in neurotoxicity and neuroprotection. <i>NeuroToxicology</i> , 2010, 31, 562-571.	1.4	26
403	Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. <i>Brain Research Bulletin</i> , 2010, 81, 543-548.	1.4	42
404	Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 166-171.	2.5	29
405	Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: Clinical-onset implications. <i>Psychiatry Research</i> , 2010, 179, 291-296.	1.7	46
406	Cannabinoid-Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, e72-91.	1.9	135
407	In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability. <i>Prostaglandins and Other Lipid Mediators</i> , 2010, 91, 90-103.	1.0	31
408	Potential antipsychotic properties of central cannabinoid (CB <sub>1</sub> ) receptor antagonists. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 208-219.	1.3	56

#	ARTICLE	IF	CITATIONS
409	An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A <sub>2A</sub> , dopamine D <sub>2</sub> , cannabinoid CB <sub>1</sub> , and metabotropic glutamate mGlu <sub>5</sub> receptors. <i>Journal of Receptor and Signal Transduction Research</i> , 2010, 30, 355-369.	1.3	30
410	The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. <i>Journal of Experimental Biology</i> , 2011, 214, 206-229.	0.8	365
412	Inhibitory Synaptic Plasticity. , 2011, , .		7
413	Bioinformatics and mathematical modelling in the study of receptor-receptor interactions and receptor oligomerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011, 1808, 1267-1283.	1.4	17
414	Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration. <i>Neuroscience Letters</i> , 2011, 489, 187-191.	1.0	15
415	Supply and demand for endocannabinoids. <i>Trends in Neurosciences</i> , 2011, 34, 304-315.	4.2	231
416	Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in <i>Cebus apella</i> monkeys. <i>Neuropharmacology</i> , 2011, 60, 418-422.	2.0	6
417	The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. <i>Neuroscience</i> , 2011, 193, 21-33.	1.1	28
418	Dopaminergic modulation of striatal neurons, circuits, and assemblies. <i>Neuroscience</i> , 2011, 198, 3-18.	1.1	118
419	The endocannabinoid system in schizophrenia. , 0, , 193-197.		0
420	Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 1.	1.0	167
421	Altered Balance of Activity in the Striatal Direct and Indirect Pathways in Mouse Models of Huntington's Disease. <i>Frontiers in Systems Neuroscience</i> , 2011, 5, 46.	1.2	70
422	Loss of striatal cannabinoid CB1 receptor function in attention-deficit/hyperactivity disorder mice with point mutation of the dopamine transporter. <i>European Journal of Neuroscience</i> , 2011, 34, 1369-1377.	1.2	23
423	Upregulation of Cannabinoid Type 1 Receptors in Dopamine D2 Receptor Knockout Mice Is Reversed by Chronic Forced Ethanol Consumption. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 19-27.	1.4	23
424	Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 33-39.	1.3	17
425	Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. , 2011, 132, 215-241.		153
426	Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. <i>European Journal of Pharmacology</i> , 2011, 655, 38-45.	1.7	64
427	Early exposure to environmental enrichment alters the expression of genes of the endocannabinoid system. <i>Brain Research</i> , 2011, 1390, 80-89.	1.1	29



#	ARTICLE	IF	CITATIONS
428	Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. <i>Neuropharmacology</i> , 2011, 61, 1070-1087.	2.0	86
429	Modulation of Striatal Projection Systems by Dopamine. <i>Annual Review of Neuroscience</i> , 2011, 34, 441-466.	5.0	1,334
430	Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. <i>Journal of Neural Transmission</i> , 2011, 118, 1661-1690.	1.4	75
431	Homeostatic changes of the endocannabinoid system in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 216-222.	2.2	45
432	Determination of endocannabinoids in nematodes and human brain tissue by liquid chromatography electrospray ionization tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 677-694.	1.2	50
433	Bidirectional plasticity in striatonigral synapses: A switch to balance direct and indirect basal ganglia pathways. <i>Learning and Memory</i> , 2011, 18, 764-773.	0.5	15
434	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D <sub>2</sub> /A <sub>2A</sub> Receptor Interaction in the Striatum: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1850-1862.	1.7	140
435	Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. <i>Journal of Psychopharmacology</i> , 2011, 25, 131-140.	2.0	32
436	Endocannabinoids mediate synaptic plasticity at glutamatergic synapses on spiny neurons within a basal ganglia nucleus necessary for song learning. <i>Journal of Neurophysiology</i> , 2011, 105, 1159-1169.	0.9	13
437	Chronic $\delta^9$ -Tetrahydrocannabinol Exposure Induces a Sensitization of Dopamine D2/3 Receptors in the Mesoaccumbens and Nigrostriatal Systems. <i>Neuropsychopharmacology</i> , 2012, 37, 2355-2367.	2.8	52
438	Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives. <i>Recent Patents on CNS Drug Discovery</i> , 2012, 7, 25-40.	0.9	65
439	Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. <i>Pharmacogenomics Journal</i> , 2012, 12, 260-266.	0.9	26
440	The Importance of the Adenosine A2A Receptor-Dopamine D2 Receptor Interaction in Drug Addiction. <i>Current Medicinal Chemistry</i> , 2012, 19, 317-355.	1.2	77
441	Anandamide Dysfunction in Prodromal and Established Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5188-5193.	0.9	30
442	Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 5141-5155.	0.9	19
443	Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5024-5035.	0.9	48
444	Cannabis Use and Psychosis: Theme Introduction. <i>Current Pharmaceutical Design</i> , 2012, 18, 4991-4998.	0.9	21
445	Endocannabinoid Modulation of Dopaminergic Motor Circuits. <i>Frontiers in Pharmacology</i> , 2012, 3, 110.	1.6	28

#	ARTICLE	IF	CITATIONS
446	Minireview: Endocannabinoids and Gonadal Hormones: Bidirectional Interactions in Physiology and Behavior. <i>Endocrinology</i> , 2012, 153, 1016-1024.	1.4	103
447	RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits. <i>Neuron</i> , 2012, 73, 347-359.	3.8	166
448	Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. <i>Neuroscience</i> , 2012, 204, 207-229.	1.1	157
449	Fear relief“toward a new conceptual frame work and what endocannabinoids gotta do with it. <i>Neuroscience</i> , 2012, 204, 159-185.	1.1	74
450	Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 36-50.	2.5	52
451	New insights on endocannabinoid transmission in psychomotor disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 51-58.	2.5	17
452	Integrating Neurotransmission in Striatal Medium Spiny Neurons. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 407-429.	0.8	79
453	Ammonia“induced deficit in corticostriatal long“term depression and its amelioration by zaprinast. <i>Journal of Neurochemistry</i> , 2012, 122, 545-556.	2.1	4
454	A Novel Mechanism of Cocaine to Enhance Dopamine D2-Like Receptor Mediated Neurochemical and Behavioral Effects. An In Vivo and In Vitro Study. <i>Neuropsychopharmacology</i> , 2012, 37, 1856-1866.	2.8	28
455	The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. <i>Neuroscience Research</i> , 2012, 72, 236-242.	1.0	53
456	The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015. <i>Brain Research Bulletin</i> , 2012, 87, 504-510.	1.4	20
457	Endocannabinoids at the synapse a decade after the <i>dis mirabilis</i> (29 March 2001): what we still do not know. <i>Journal of Physiology</i> , 2012, 590, 2203-2212.	1.3	71
459	Role of the ABCE1 gene in human lung adenocarcinoma. <i>Oncology Reports</i> , 2012, 27, 965-970.	1.2	28
460	Muscarinic Modulation of Striatal Function and Circuitry. <i>Handbook of Experimental Pharmacology</i> , 2012, , 223-241.	0.9	127
461	Adenosine A2A“cannabinoid CB1 receptor interaction: An integrative mechanism in striatal glutamatergic neurotransmission. <i>Brain Research</i> , 2012, 1476, 108-118.	1.1	25
462	Muscarinic Receptors. <i>Handbook of Experimental Pharmacology</i> , 2012, , .	0.9	12
463	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	1.1	18
464	Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the “Mirror Effect“of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2012, 3, 85.	1.3	19

#	ARTICLE	IF	CITATIONS
465	Medication Development for the Treatment of Cocaine Addiction – Progress at Preclinical and Clinical Levels. , 2012, , .		0
466	Psychopharmacology of the endocannabinoids: far beyond anandamide. <i>Journal of Psychopharmacology</i> , 2012, 26, 7-22.	2.0	39
467	Characterization of the Effects of Reuptake and Hydrolysis Inhibition on Interstitial Endocannabinoid Levels in the Brain: An in Vivo Microdialysis Study. <i>ACS Chemical Neuroscience</i> , 2012, 3, 407-417.	1.7	61
468	Quinpirole elicits differential in vivo changes in the pre- and postsynaptic distributions of dopamine D2 receptors in mouse striatum: relation to cannabinoid-1 (CB1) receptor targeting. <i>Psychopharmacology</i> , 2012, 221, 101-113.	1.5	10
469	Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. <i>Psychopharmacology</i> , 2012, 222, 425-438.	1.5	16
470	Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat. <i>Neurotoxicology and Teratology</i> , 2012, 34, 63-71.	1.2	35
471	Pretreatment with $\delta^9$ -tetrahydrocannabinol (THC) increases cocaine-stimulated activity in adolescent but not adult male rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 587-591.	1.3	24
472	Sex differences in cannabinoid receptor-1 (CB1) pharmacology in mice selectively bred for high voluntary wheel-running behavior. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 101, 528-537.	1.3	50
473	Effects of cannabinoids $\delta^9$ -tetrahydrocannabinol, $\delta^9$ -tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. <i>Phytomedicine</i> , 2012, 19, 819-824.	2.3	56
474	Behavioral Neurobiology of Alcohol Addiction. <i>Current Topics in Behavioral Neurosciences</i> , 2013, 13, v-vii.	0.8	13
475	Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. <i>Psychopharmacology</i> , 2013, 228, 401-409.	1.5	31
476	Molecular and cellular mechanisms of dopamine-mediated behavioral plasticity in the striatum. <i>Neurobiology of Learning and Memory</i> , 2013, 105, 63-80.	1.0	54
477	Downregulation of cannabinoid receptor 1 from neuropeptide $\gamma$ -interneurons in the basal ganglia of patients with Huntington's disease and mouse models. <i>European Journal of Neuroscience</i> , 2013, 37, 429-440.	1.2	46
478	Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1582-1594.	3.3	41
479	Optogenetic insights into striatal function and behavior. <i>Behavioural Brain Research</i> , 2013, 255, 44-54.	1.2	87
480	Functional imaging of implicit marijuana associations during performance on an Implicit Association Test (IAT). <i>Behavioural Brain Research</i> , 2013, 256, 494-502.	1.2	75
481	Disease-Specific Heteromerization of G-Protein-Coupled Receptors That Target Drugs of Abuse. <i>Progress in Molecular Biology and Translational Science</i> , 2013, 117, 207-265.	0.9	28
482	Comparative effects of parathion and chlorpyrifos on extracellular endocannabinoid levels in rat hippocampus: Influence on cholinergic toxicity. <i>Toxicology and Applied Pharmacology</i> , 2013, 272, 608-615.	1.3	17

#	ARTICLE	IF	CITATIONS
483	Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 363-377.	1.5	22
484	The role of endocannabinoids in pain modulation. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 64-80.	1.0	70
485	The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects. <i>Journal of Applied Toxicology</i> , 2013, 33, 246-264.	1.4	26
486	Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: Role of CB1 receptors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 47, 77-84.	2.5	18
487	Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. <i>Schizophrenia Research</i> , 2013, 148, 145-150.	1.1	65
488	Computational evaluation of small molecule inhibitors of RGS4 to regulate the dopaminergic control of striatal LTD. <i>Egyptian Journal of Medical Human Genetics</i> , 2013, 14, 135-142.	0.5	1
489	Sensory gating, Cannabinoids and Schizophrenia. <i>Neuropharmacology</i> , 2013, 67, 66-77.	2.0	28
490	Anandamide-CB1 Receptor Signaling Contributes to Postnatal Ethanol-Induced Neonatal Neurodegeneration, Adult Synaptic, and Memory Deficits. <i>Journal of Neuroscience</i> , 2013, 33, 6350-6366.	1.7	94
491	The Volitional Nature of Nicotine Exposure Alters Anandamide and Oleoylethanolamide Levels in the Ventral Tegmental Area. <i>Neuropsychopharmacology</i> , 2013, 38, 574-584.	2.8	40
492	The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. <i>Behavioural Pharmacology</i> , 2013, 24, 640-652.	0.8	12
493	Cannabis Use and Psychosis. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 136-139.	0.5	0
494	Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1277-1293.	1.0	33
495	What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 661-670.	1.1	53
496	Crosstalk between Dopamine D <sub>2</sub> receptors and cannabinoid CB <sub>1</sub> receptors regulates CNR1 promoter activity via ERK1/2 signaling. <i>Journal of Neurochemistry</i> , 2013, 127, 163-176.	2.1	19
497	Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. <i>Addiction Biology</i> , 2013, 18, 955-969.	1.4	40
498	Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 661-676.	1.0	32
499	Neuropeptide Receptors. <i>Colloquium Series on Neuropeptides</i> , 2013, 2, 1-167.	1.0	3
500	Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System. <i>Current Pharmaceutical Design</i> , 2014, 20, 4707-4722.	0.9	69

#	ARTICLE	IF	CITATIONS
501	Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow. PLoS ONE, 2014, 9, e108282.	1.1	31
502	Characterization of N-Acyl Phosphatidylethanolamine-Specific Phospholipase-D Isoforms in the Nematode <i>Caenorhabditis elegans</i> . PLoS ONE, 2014, 9, e113007.	1.1	23
503	Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 183.	1.0	9
504	Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. <i>Frontiers in Integrative Neuroscience</i> , 2014, 8, 22.	1.0	19
505	Nonclassic Signaling in the Brain. , 2014, , 239-255.		0
506	Neurochemical Communication: The Case of Endocannabinoids. , 2014, , .		3
508	Cannabinoids and the Neural Actions of Alcohol. , 2014, , 267-289.		1
509	Long-term depression at distinct glutamatergic synapses in the basal ganglia. <i>Reviews in the Neurosciences</i> , 2014, 25, 741-54.	1.4	5
510	Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3149-56.	3.3	180
511	Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction. <i>European Journal of Neuroscience</i> , 2014, 39, 1189-1201.	1.2	27
512	More surprises lying ahead. The endocannabinoids keep us guessing. <i>Neuropharmacology</i> , 2014, 76, 228-234.	2.0	107
513	Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. <i>Neuropharmacology</i> , 2014, 87, 214-221.	2.0	24
514	Effects of $\delta^9$ -tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. <i>Psychopharmacology</i> , 2014, 231, 2385-2393.	1.5	7
515	Delineation of Domains Within the Cannabinoid CB1 and Dopamine D2 Receptors That Mediate the Formation of the Heterodimer Complex. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 10-21.	1.1	37
516	Physical activity and the endocannabinoid system: an overview. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2681-2698.	2.4	80
518	Low level chlorpyrifos exposure increases anandamide accumulation in juvenile rat brain in the absence of brain cholinesterase inhibition. <i>NeuroToxicology</i> , 2014, 43, 82-89.	1.4	43
519	Uridine decreases morphine-induced behavioral sensitization by decreasing dorsal striatal dopamine release possibly via agonistic effects at GABAA receptors. <i>European Neuropsychopharmacology</i> , 2014, 24, 1557-1566.	0.3	7
520	Phosphatidylserine in the brain: Metabolism and function. <i>Progress in Lipid Research</i> , 2014, 56, 1-18.	5.3	256

#	ARTICLE	IF	CITATIONS
521	Levodopa-Induced Dyskinesia in Parkinson's Disease. , 2014, , .		5
522	Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 1-10.	2.5	38
523	Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 195-199.	2.5	13
524	Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute d-amphetamine. Behavioural Brain Research, 2014, 270, 261-269.	1.2	20
525	The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184. Pharmacology Biochemistry and Behavior, 2014, 124, 153-159.	1.3	40
526	The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiology of Aging, 2014, 35, 2603-2616.	1.5	71
527	Reductions in Endocannabinoid Levels and Enhanced Coupling of Cannabinoid Receptors in the Striatum are Accompanied by Cognitive Impairments in the Al <sup>2</sup> PPswe/PS1 <sup>E9</sup> Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 227-245.	1.2	33
528	Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders. Focus (American Psychiatric Publishing), 2015, 13, 307-316.	0.4	7
529	Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets. Pharmacology Research and Perspectives, 2015, 3, e00104.	1.1	4
530	Cannabinoids and Endocannabinoids. , 2015, , 1-31.		2
531	Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling. Brain Sciences, 2015, 5, 456-493.	1.1	40
532	Endocannabinoid Regulation of Neuroendocrine Systems. International Review of Neurobiology, 2015, 125, 163-201.	0.9	29
533	Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior. Neuroscience, 2015, 290, 594-607.	1.1	12
534	Cannabinoids and schizophrenia. , 2015, , 193-204.		1
535	Cannabinoids and Huntington's disease. , 2015, , 61-97.		3
536	Cannabinoids in Parkinson's disease. , 2015, , 35-59.		7
537	Input- and Cell-Type-Specific Endocannabinoid-Dependent LTD in the Striatum. Cell Reports, 2015, 10, 75-87.	2.9	101
538	Remote modulation of neural activities via near-infrared triggered release of biomolecules. Biomaterials, 2015, 65, 76-85.	5.7	65

#	ARTICLE	IF	CITATIONS
539	Cocaine-Induced Behavioral Sensitization Is Associated With Changes in the Expression of Endocannabinoid and Glutamatergic Signaling Systems in the Mouse Prefrontal Cortex. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	27
541	Colocalization of cannabinoid receptor 1 with somatostatin and neuronal nitric oxide synthase in rat brain hippocampus. <i>Brain Research</i> , 2015, 1622, 114-126.	1.1	7
543	Downstream effects of endocannabinoid on blood cells: implications for health and disease. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3235-3252.	2.4	10
544	Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. <i>Molecular Neurodegeneration</i> , 2015, 10, 17.	4.4	90
545	Endocannabinoids and striatal function. <i>Behavioural Pharmacology</i> , 2015, 26, 59-72.	0.8	35
546	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015, 67, 872-1004.	7.1	125
547	Endocannabinoid signaling mediates oxytocin-driven social reward. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14084-14089.	3.3	163
548	Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice. <i>Addiction Biology</i> , 2015, 20, 91-103.	1.4	40
549	Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission. <i>Journal of Neuroscience</i> , 2015, 35, 14057-14069.	1.7	46
550	Endocannabinoid signalling in reward and addiction. <i>Nature Reviews Neuroscience</i> , 2015, 16, 579-594.	4.9	370
551	Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. <i>Parkinson's Disease</i> , 2016, 2016, 1-19.	0.6	17
552	The Cholinergic Interneuron of the Striatum. <i>Handbook of Behavioral Neuroscience</i> , 2016, , 137-155.	0.7	2
553	Dopaminergic Modulation of Glutamatergic Signaling in Striatal Spiny Projection Neurons. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 179-196.	0.7	1
554	Endocannabinoid Signaling in the Striatum. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 197-215.	0.7	2
555	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 459-476.	0.7	1
556	Maternal separation and early stress cause long-lasting effects on dopaminergic and endocannabinergic systems and alters dendritic morphology in the nucleus accumbens and frontal cortex in rats. <i>Developmental Neurobiology</i> , 2016, 76, 819-831.	1.5	36
557	Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action. <i>Neurobiology of Disease</i> , 2016, 94, 179-195.	2.1	69
558	Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons. <i>Molecular Pharmacology</i> , 2016, 89, 652-666.	1.0	38

#	ARTICLE	IF	CITATIONS
559	Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions. <i>Journal of Neuroscience</i> , 2016, 36, 10230-10238.	1.7	52
560	Cannabinoid-dopamine interactions in the physiology and pathophysiology of the basal ganglia. <i>British Journal of Pharmacology</i> , 2016, 173, 2069-2079.	2.7	56
561	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 94-105.	2.0	51
562	Molecular Mechanism: ERK Signaling, Drug Addiction, and Behavioral Effects. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 137, 1-40.	0.9	50
563	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. <i>Neuropharmacology</i> , 2016, 101, 341-350.	2.0	16
564	An Introduction to the Endogenous Cannabinoid System. <i>Biological Psychiatry</i> , 2016, 79, 516-525.	0.7	750
565	Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. <i>Neuropharmacology</i> , 2016, 101, 460-470.	2.0	12
566	Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. <i>Psychopharmacology</i> , 2016, 233, 1765-1777.	1.5	39
567	Microglial phenotypes in Parkinson's disease and animal models of the disease. <i>Progress in Neurobiology</i> , 2017, 155, 57-75.	2.8	202
568	Because difficulty is not the same for everyone: the impact of complexity in working memory is associated with cannabinoid 1 receptor genetic variation in young adults. <i>Memory</i> , 2017, 25, 335-343.	0.9	9
569	Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence. <i>Addiction Biology</i> , 2017, 22, 1366-1377.	1.4	20
570	The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice. <i>Neuropharmacology</i> , 2017, 116, 132-141.	2.0	3
571	Cannabinoids in Parkinson's Disease. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 21-29.	1.5	71
572	Endocannabinoid Signaling in the Control of Social Behavior. <i>Trends in Neurosciences</i> , 2017, 40, 385-396.	4.2	76
573	Neurotransmission systems in Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2017, 28, 509-536.	1.4	54
574	The CB1 Receptor as the Cornerstone of Exostasis. <i>Neuron</i> , 2017, 93, 1252-1274.	3.8	60
575	The Quinpirole Hypolocomotive Effects are Strain and Route of Administration Dependent in SHR and SLA16 Isogenic Rats. <i>Behavior Genetics</i> , 2017, 47, 552-563.	1.4	14
576	Consequence of dopamine D2 receptor blockade on the hyperphagic effect induced by cannabinoid CB1 and CB2 receptors in layers. <i>British Poultry Science</i> , 2017, 58, 585-593.	0.8	18



#	ARTICLE	IF	CITATIONS
577	Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens. <i>Neuron</i> , 2017, 96, 1112-1126.e5.	3.8	90
578	Microdialysis Coupled with LC-MS/MS for In Vivo Neurochemical Monitoring. <i>AAPS Journal</i> , 2017, 19, 1284-1293.	2.2	57
579	Cannabinoid Receptors and Their Signaling Mechanisms. , 2017, , 25-62.		1
580	The Endocannabinoid System and Parkinson Disease. , 2017, , 63-81.		4
581	Putative Role of Endocannabinoids in Schizophrenia. , 2017, , 83-113.		0
582	The Endocannabinoid System and Human Brain Functions. , 2017, , 115-186.		3
583	Antihyperalgesic Activities of Endocannabinoids in a Mouse Model of Antiretroviral-Induced Neuropathic Pain. <i>Frontiers in Pharmacology</i> , 2017, 8, 136.	1.6	26
584	Cannabis: A Treasure Trove or Pandora's Box?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2017, 17, 1223-1291.	1.1	67
585	Alterations of eicosanoids and related mediators in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2018, 102, 168-178.	1.5	19
586	Access to the CNS: Biomarker Strategies for Dopaminergic Treatments. <i>Pharmaceutical Research</i> , 2018, 35, 64.	1.7	9
587	Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2146-2161.	1.7	79
588	Different effects of chronic THC on the neuroadaptive response of dopamine D2/3 receptor-mediated signaling in roman high- and roman low-avoidance rats. <i>Synapse</i> , 2018, 72, e22023.	0.6	3
589	Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 825-849.	2.0	37
590	Polyunsaturated fatty acids and endocannabinoids in health and disease. <i>Nutritional Neuroscience</i> , 2018, 21, 695-714.	1.5	77
591	Endogenous dopamine and endocannabinoid signaling mediate cocaine-induced reversal of AMPAR synaptic potentiation in the nucleus accumbens shell. <i>Neuropharmacology</i> , 2018, 131, 154-165.	2.0	10
592	Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations. <i>Scientific Reports</i> , 2018, 8, 13787.	1.6	25
593	Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. <i>Addiction Biology</i> , 2018, 23, 1251-1261.	1.4	4
594	Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 305-345.	0.9	16

#	ARTICLE	IF	CITATIONS
595	Dual Dopaminergic Regulation of Corticostriatal Plasticity by Cholinergic Interneurons and Indirect Pathway Medium Spiny Neurons. <i>Cell Reports</i> , 2018, 24, 2883-2893.	2.9	49
596	Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine. <i>Neuropsychopharmacology</i> , 2018, 43, 2083-2092.	2.8	36
597	Brain endocannabinoid signaling exhibits remarkable complexity. <i>Brain Research Bulletin</i> , 2018, 142, 33-46.	1.4	8
598	Loren Parsons' contribution to addiction neurobiology. <i>Addiction Biology</i> , 2018, 23, 1207-1222.	1.4	6
599	Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. <i>CNS Drugs</i> , 2018, 32, 605-619.	2.7	36
600	Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors. <i>Neurotoxicity Research</i> , 2018, 34, 547-558.	1.3	23
601	Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models. <i>Pain Research and Management</i> , 2018, 2018, 1-9.	0.7	25
602	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. <i>Biochemical Pharmacology</i> , 2018, 157, 67-84.	2.0	75
603	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 118, 1-8.	2.1	22
604	Brain activity of anandamide: a rewarding bliss?. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 309-323.	2.8	53
605	Levels of endocannabinoid metabolizing enzymes are not related with BDNF levels in patients with schizophrenia: a case-controlled study. <i>Journal of Theoretical Social Psychology</i> , 2019, 29, 441-445.	1.2	1
606	Recent Advances in Cannabinoid Physiology and Pathology. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	5
607	Endocannabinoid System and Alcohol Abuse Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1162, 89-127.	0.8	17
608	Possible Role of the Endocannabinoid System in Tourette Syndrome. , 2019, , .		4
609	Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2019, 97, 1655-1664.	1.3	10
610	Endocannabinoids Interact With the Dopaminergic System to Increase Sexual Motivation: Lessons From the Sexual Satiation Phenomenon. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 184.	1.0	16
611	Oscillation dynamics in an extended model of thalamic-basal ganglia. <i>Nonlinear Dynamics</i> , 2019, 98, 1065-1080.	2.7	16
612	Blood-Based Biomarkers of Quinpirole Pharmacology: Cluster-Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 107-117.	1.3	2

#	ARTICLE	IF	CITATIONS
613	Molecular neuroscience at its "high": bibliometric analysis of the most cited papers on endocannabinoid system, cannabis and cannabinoids. <i>Journal of Cannabis Research</i> , 2019, 1, 4.	1.5	7
614	Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole. <i>Anesthesia and Analgesia</i> , 2019, 129, 263-268.	1.1	8
615	Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. <i>Molecules</i> , 2019, 24, 1350.	1.7	28
616	The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. <i>CNS Drugs</i> , 2019, 33, 417-430.	2.7	24
617	Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 31.	0.7	112
618	The Possible Mechanism of the Appearance of Nightmares in Post-Traumatic Stress Disorder and Approaches to Their Prevention. <i>Neurochemical Journal</i> , 2019, 13, 320-334.	0.2	2
619	Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease. <i>Brain Research Bulletin</i> , 2019, 146, 244-252.	1.4	20
620	A competitive model for striatal action selection. <i>Brain Research</i> , 2019, 1713, 70-79.	1.1	69
621	Long-term depression induced by endogenous cannabinoids produces neuroprotection via astroglial CB <sub>1</sub> R after stroke in rodents. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1122-1137.	2.4	18
622	The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 96, 109745.	2.5	21
623	Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. <i>Psychological Medicine</i> , 2020, 50, 1862-1871.	2.7	13
624	D <sub>2</sub> autoreceptor switches CB <sub>2</sub> receptor effects on [ <sup>3</sup> H]dopamine release in the striatum. <i>Synapse</i> , 2020, 74, e22139.	0.6	10
625	Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia. <i>Neurotoxicity Research</i> , 2020, 37, 12-29.	1.3	33
626	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. <i>Molecules</i> , 2020, 25, 4036.	1.7	52
627	Druggable Targets in Endocannabinoid Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1274, 177-201.	0.8	13
628	URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels. <i>Journal of Psychopharmacology</i> , 2021, 35, 875-884.	2.0	8
629	Differential effects of <sup>9</sup> -tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model. <i>PLoS ONE</i> , 2020, 15, e0230238.	1.1	15
630	The role of catecholamines in modulating responses to stress: Sex-specific patterns, implications, and therapeutic potential for post-traumatic stress disorder and opiate withdrawal. <i>European Journal of Neuroscience</i> , 2020, 52, 2429-2465.	1.2	10

#	ARTICLE	IF	CITATIONS
631	Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor. <i>Neurobiology of Disease</i> , 2021, 148, 105214.	2.1	8
632	Antinociceptive and sedative activity of <i>Vernonia patula</i> and predictive interactions of its phenolic compounds with the cannabinoid type 1 receptor. <i>Phytotherapy Research</i> , 2021, 35, 1069-1079.	2.8	7
633	Neuroprotective and neurotoxic effects of endocannabinoid-like compounds, N-arachidonoyl dopamine and N-docosahexaenoyl dopamine in differentiated cultures of induced pluripotent stem cells derived from patients with Parkinson's disease. <i>NeuroToxicology</i> , 2021, 82, 108-118.	1.4	5
634	Effects of High-Fat Diet and Maternal Binge-Like Alcohol Consumption and Their Influence on Cocaine Response in Female Mice Offspring. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 77-88.	1.0	2
635	The endocannabinoid system in the adipose organ. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 51-60.	2.6	12
636	Restoring glutamate homeostasis in the nucleus accumbens via endocannabinoid-mimetic drug prevents relapse to cocaine seeking behavior in rats. <i>Neuropsychopharmacology</i> , 2021, 46, 970-981.	2.8	19
637	Neurexin1 <sup>Δ</sup> differentially regulates synaptic efficacy within striatal circuits. <i>Cell Reports</i> , 2021, 34, 108773.	2.9	11
638	Mechanism for differential recruitment of orbitostriatal transmission during actions and outcomes following chronic alcohol exposure. <i>ELife</i> , 2021, 10, .	2.8	16
639	Molecular Docking and Molecular Dynamics Simulation Studies of Triterpenes from <i>Vernonia patula</i> with the Cannabinoid Type 1 Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3595.	1.8	10
640	Cannabinoids, reward processing, and psychosis. <i>Psychopharmacology</i> , 2022, 239, 1157-1177.	1.5	12
641	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 614811.	1.6	24
642	Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation. <i>International Immunopharmacology</i> , 2021, 94, 107431.	1.7	15
643	Unconventional high-value products from microalgae: A review. <i>Bioresource Technology</i> , 2021, 329, 124895.	4.8	68
644	Heteromerization of dopaminergic receptors in the brain: Pharmacological implications. <i>Pharmacological Research</i> , 2021, 170, 105600.	3.1	14
645	Rapid quantification of extracellular neurotransmitters in mouse brain by PESI/MS/MS and longitudinal data analysis using the R and Stan-based Bayesian state-space model. <i>Talanta</i> , 2021, 234, 122620.	2.9	6
646	Endocannabinoids and aging: Inflammation, neuroplasticity, mood and pain. <i>Vitamins and Hormones</i> , 2021, 115, 129-172.	0.7	7
647	Lipids   The Endocannabinoid System. , 2021, , 776-784.		1
648	The Endocannabinoid System. , 2008, , 343-384.		3

#	ARTICLE	IF	CITATIONS
649	Anatomical Distribution of Receptors, Ligands and Enzymes in the Brain and in the Spinal Cord: Circuitries and Neurochemistry. , 2008, , 161-201.		46
650	Endocannabinoids at the Synapse: Retrograde Signaling and Presynaptic Plasticity in the Brain. , 2008, , 203-236.		7
651	The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia. , 2008, , 423-483.		14
652	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. , 2013, , 73-101.		1
653	Cannabinoids and Endocannabinoids. , 2016, , 1811-1841.		3
654	The Corticostriatal Pathway in Parkinsonâ€™s Disease. , 2009, , 1-18.		3
655	Metabolism and physiological significance of anandamide and 2-arachidonoylglycerol, endogenous cannabinoid receptor ligands. , 2004, , 211-237.		12
656	Cannabinoids and Pain. , 2007, , 265-306.		55
657	Drug Addiction. Current Topics in Behavioral Neurosciences, 2009, 1, 309-346.	0.8	31
658	Touretteâ€™s Syndrome. Current Topics in Behavioral Neurosciences, 2009, 1, 397-410.	0.8	5
659	PET Imaging of Endocannabinoid System. , 2014, , 249-319.		6
660	ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain. European Journal of Pharmacology, 2020, 881, 173194.	1.7	10
661	Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level of n-6 fatty acids as another critical factor. Journal of Lipid Research, 2001, 42, 1655-1663.	2.0	123
663	Synaptic Triad in the Neostriatum. Frontiers in Neuroscience, 2011, , 71-104.	0.0	1
664	Cannabinoid receptors and endocannabinoids: Evidence for new players. , 2006, 8, E298.		127
665	The Endocannabinoid System. Journal of Cannabis Therapeutics, 2001, 1, 43-62.	1.2	8
666	Cannabinoid CB1 Receptor Activation Mediates the Opposing Effects of Amphetamine on Impulsive Action and Impulsive Choice. PLoS ONE, 2011, 6, e25856.	1.1	61
667	Temporal Changes of CB1 Cannabinoid Receptor in the Basal Ganglia as a Possible Structure-Specific Plasticity Process in 6-OHDA Lesioned Rats. PLoS ONE, 2013, 8, e76874.	1.1	16

#	ARTICLE	IF	CITATIONS
668	Impaired Ethanol-Induced Sensitization and Decreased Cannabinoid Receptor-1 in a Model of Posttraumatic Stress Disorder. PLoS ONE, 2016, 11, e0155759.	1.1	14
669	The Endocannabinoid/Endovanilloid System and Depression. Current Neuropharmacology, 2014, 12, 462-474.	1.4	31
670	Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors. CNS and Neurological Disorders - Drug Targets, 2010, 9, 601-615.	0.8	19
671	The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases. International Journal of High Risk Behaviors & Addiction, 2013, 2, 100-106.	0.1	35
672	Sistema cannabinoide endógeno: ligandos y receptores acoplados a mecanismos de transducción de señales. Revista De Psicología De La Salud, 2000, 12, 59.	0.2	1
674	Dopamine-Endocannabinoid Interactions in Parkinson's Disease. , 2009, , 1-21.		2
675	Schizophrenia. Current Topics in Behavioral Neurosciences, 2009, 1, 387-396.	0.8	0
676	Dopaminergic Modulation of Glutamatergic Signaling in Striatal Medium Spiny Neurons. , 2010, , 175-191.		0
677	Dopamine D3 Receptor Antagonist SB-277011A Influences Cell Firing in the Rat Ventral Tegmental Area, Parallel Role with the Cannabinoid System in Addiction and Neuropsychiatry Disorders?. The Open Neuropsychopharmacology Journal, 2009, 2, 86-92.	0.3	1
678	7.3 Dopaminergic Modulation of Striatal Glutamatergic Signaling in Health and Parkinson's Disease. , 2009, , 349-368.		0
679	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. Handbook of Behavioral Neuroscience, 2010, , 219-229.	0.7	0
680	Endocannabinoid Mediated Long-Term Depression at Inhibitory Synapses. , 2011, , 149-166.		0
682	Medication Overuse Headache: Causes, Consequences, and Treatment. , 2012, , 351-362.		0
683	Endocannabinoids, Monoamines and Stress. , 2013, , 173-212.		0
684	Canabinoides y endocannabinoides como herramienta para el desarrollo de posibles antineoplásicos en caninos. Una revisión. Orinoquia, 2014, 18, 68.	0.1	0
685	Cannabinoids and Levodopa-Induced Dyskinesia. , 2014, , 245-264.		1
686	Endocannabinoid-Dependent Synaptic Plasticity in the Striatum. , 2017, , 109-153.		0
688	Cannabis, Cannabinoide und das Endocannabinoidsystem. , 2019, , 1-36.		0

#	ARTICLE	IF	CITATIONS
689	Endocannabinoidsystem und Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter. Nervenheilkunde, 2019, 38, 662-666.	0.0	0
690	Review of Research Progress on Endocannabinoids in Neurodegenerative Diseases. International Journal of Psychiatry and Neurology, 2020, 09, 20-25.	0.1	0
692	ABHD6 Controls Amphetamine-Stimulated Hyperlocomotion: Involvement of CB <sub>1</sub> Receptors. Cannabis and Cannabinoid Research, 2022, 7, 188-198.	1.5	6
697	N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351 Pt 3, 817-24.	1.7	99
702	The effect of AM281, a cannabinoid antagonist, on memory performance during spontaneous morphine withdrawal in mice. Research in Pharmaceutical Sciences, 2013, 8, 59-64.	0.6	6
704	2-Arachidonoylglycerol mobilization following brief synaptic stimulation in the dorsal lateral striatum requires glutamatergic and cholinergic neurotransmission. Neuropharmacology, 2022, 205, 108916.	2.0	11
705	Basic mechanisms of plasticity and learning. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 21-34.	1.0	9
706	Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid- and steroid-based interventions. International Review of Movement Disorders, 2022, , .	0.1	0
707	ADHD: Causes and alternative types of intervention. Scientific Electronic Archives, 2022, 15, .	0.1	1
708	Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease. Frontiers in Cellular Neuroscience, 2022, 16, 832854.	1.8	10
709	Class A and C GPCR dimers in neurodegenerative diseases. Current Neuropharmacology, 2022, 20, .	1.4	2
710	Striatonigrostriatal Spirals in Addiction. Frontiers in Neural Circuits, 2021, 15, 803501.	1.4	0
714	The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies. Metabolites, 2022, 12, 541.	1.3	3
715	Cannabinoids. Advances in Neurotoxicology, 2022, , .	0.7	0
716	Dietary PUFAs and Exercise Dynamic Actions on Endocannabinoids in Brain: Consequences for Neural Plasticity and Neuroinflammation. Advances in Nutrition, 2022, 13, 1989-2001.	2.9	8
717	Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors. Neurochemical Research, 2022, 47, 2899-2908.	1.6	5
718	Cannabinoids and Endocannabinoids. , 2022, , 2129-2157.		0
719	Acute and chronic effects by nicotine on striatal neurotransmission and synaptic plasticity in the female rat brain. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2

#	ARTICLE	IF	CITATIONS
720	Endocannabinoid 2-Arachidonoylglycerol Synthesis and Metabolism at Neuronal Nuclear Matrix Fractions Derived from Adult Rat Brain Cortex. International Journal of Molecular Sciences, 2023, 24, 3165.	1.8	1
721	THC and CBD: Villain versus Hero? Insights into Adolescent Exposure. International Journal of Molecular Sciences, 2023, 24, 5251.	1.8	7
723	Neurobiology of the endocannabinoid system and relevance to cannabis use. , 2023, , 253-264.		0